Zimmer Biomet (ZBH) Q3 2026 Earnings Call Transcript
Zimmer Biomet (ZBH) reported Q3 2026 net sales of $2.63B, up 3.7% in constant currency. Growth was driven by hips, S.E.T., and technology, while knees declined 2.6%. The company raised its 2026 guidance, expecting 3% to 3.5% constant currency sales growth and $8.50 to $8.60 adjusted EPS. Strategic priorities include sales force transition, robotics expansion, and diversification.
How this was made
The 30-second read
Why it matters
The key tradable update is the company’s raised 2026 organic constant-currency sales growth and adjusted EPS guidance, alongside operational commentary on U.S. sales-force transition progress and ongoing knee and China pressures.
Market read
Raised full-year guidance and quantified headwinds create a clear near-term repricing opportunity, with traders likely to weigh franchise strength against knee and China risks.
What to watch
Investors may discount the guidance if robotics adoption (ROSA, TMINI) or OrthoGrid expansion does not sustain, or if the Monogram 510(k) timing slips despite the stated FDA filing plan.
Background
The article is a transcript of Zimmer Biomet’s Q3 2026 earnings call, covering quarterly performance, strategic priorities, and an updated full-year 2026 outlook.
Ticker impact
Zimmer Biomet raised 2026 organic constant-currency sales growth guidance to 3.0% to 3.5% and adjusted EPS to $8.50 to $8.60 after Q3 results.
Likely upward bias as traders reprice 2026 earnings power, while monitoring knee and China risks highlighted in the outlook.
The transcript explicitly states raised full-year guidance ranges and ties them to specific franchise performance and quantified headwinds (U.S. sales force disruption and China-related impacts).
Market effects
Orthopedic medtech peers may see read-across on demand durability for robotics, data/AI, and recurring-revenue platforms versus slower knee segments.
U.S. sales-force transition progress and Japan momentum (iodine-coated launch) may influence regional sentiment for orthopedic implant demand.
Global orthopedic procedure volumes and adoption of robotic-assisted surgery could be sentiment drivers, though the article is company-specific.
Counterpoint
The raised outlook still embeds meaningful knee and China headwinds, so the market may focus on whether the U.S. sales-force transition and knee stabilization deliver fast enough.
Key entities
- companyZimmer Biomet
Orthopedic medical device company reporting Q3 2026 results and raising 2026 guidance, including adjusted EPS and organic constant-currency sales growth.
- productMonogram
Robotics system referenced with an expected FDA 510(k) filing and a revised launch timing for a fully autonomous version.
- partnerTHINK Surgical
Named in a multiyear limited distribution and supply agreement for an exclusive version of the TMINI robotic system compatible with Persona Knee.